Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial
The Lancet Respiratory Medicine (2021) - Comments
pubmed: 34126053  doi: 10.1016/s2213-2600(21)00214-9  issn: 2213-2619  issn: 2213-2600 

Axel Bauer, Michael Schreinlechner, Nikolay Sappler, Theresa Dolejsi, Herbert Tilg, Benedikt A Aulinger, Günter Weiss, Rosa Bellmann-Weiler, Christian Adolf, Dominik Wolf, Markus Pirklbauer, Ivo Graziadei, Hannes Gänzer, Christian Von Bary, Andreas E May, Ewald Wöll, Wolfgang Von Scheidt, Tienush Rassaf, Daniel Duerschmied, Christoph Brenner